Stephens Consulting’s Zymeworks ZYME Stock Holding History

Stephens Consulting’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30	Closed	-$358	–	2044
2025 Q1	$358	Buy	+30	New	+$409	﹤0.01%	1280

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Stephens Consulting's ZYME Position: Q2 2025 in Review

Stephens Consulting sold out of Zymeworks (ZYME) in Q2 2025, closing a stake of 30 shares — an estimated $358 sold.

Stephens Consulting first reported a position in ZYME in Q1 2025 and held it in 1 quarter. The position peaked at $358 in Q1 2025. 181 funds tracked by Wall St. Rank hold ZYME as of Q2 2025.

Stephens Consulting reported no remaining Zymeworks position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 30 Zymeworks shares in Q2 2025, an estimated $358.
Stephens Consulting first reported a position in Zymeworks in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Zymeworks position peaked at $358 in Q1 2025.
181 funds tracked by Wall St. Rank held Zymeworks as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.